This Breakthrough Cancer Treatment Can Cut Risk by 42 Percent
A groundbreaking phase 3 clinical trial reveals that a personalized mRNA vaccine from Merck and Moderna significantly cuts the risk of melanoma returning.
We haven't written up this one. Inc. has the full story — the link below goes straight to it.